Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Perseus Proteomics, Inc. ( (JP:4882) ) has shared an announcement.
Perseus Proteomics, Inc. has announced an extension of the Phase I/II clinical trial period for its anti-transferrin receptor 1 antibody, PPMX-T003, targeting aggressive NK-cell leukemia, due to difficulties in patient enrollment. The trial will now continue until March 31, 2027, with the potential impact on the company’s business performance still under review.
More about Perseus Proteomics, Inc.
Perseus Proteomics, Inc. operates in the biotechnology industry, focusing on the development of therapeutic antibodies. The company is engaged in creating innovative treatments for rare and challenging diseases, with a particular emphasis on aggressive NK-cell leukemia.
Average Trading Volume: 308,386
Technical Sentiment Signal: Sell
Current Market Cap: Yen4.59B
For a thorough assessment of 4882 stock, go to TipRanks’ Stock Analysis page.